21 U.S. Code § 379d–4 - Reporting requirements

Status message

There are 2 Updates Pending. Select the tab below to view.
(a) Generic drugs
Beginning with fiscal year 2013 and ending after fiscal year 2017, not later than 120 days after the end of each fiscal year for which fees are collected under subpart 7 of part C, the Secretary shall prepare and submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report concerning, for all applications for approval of a generic drug under section 355 (j) of this title, amendments to such applications, and prior approval supplements with respect to such applications filed in the previous fiscal year—
(1) the number of such applications that met the goals identified for purposes of subpart 7 of part C, in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate and the Chairman of the Committee on Energy and Commerce of the House of Representatives, as set forth in the Congressional Record;
(2) the average total time to decision by the Secretary for applications for approval of a generic drug under section 355 (j) of this title, amendments to such applications, and prior approval supplements with respect to such applications filed in the previous fiscal year, including the number of calendar days spent during the review by the Food and Drug Administration and the number of calendar days spent by the sponsor responding to a complete response letter;
(3) the total number of applications under section 355 (j) of this title, amendments to such applications, and prior approval supplements with respect to such applications that were pending with the Secretary for more than 10 months on July 9, 2012; and
(4) the number of applications described in paragraph (3) on which the Food and Drug Administration took final regulatory action in the previous fiscal year.
(b) Biosimilar biological products
(1) In general
Beginning with fiscal year 2014, not later than 120 days after the end of each fiscal year for which fees are collected under subpart 8 of part C, the Secretary shall prepare and submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report concerning—
(A) the number of applications for approval filed under section 262 (k) of title 42; and
(B) the percentage of applications described in subparagraph (A) that were approved by the Secretary.
(2) Additional information
As part of the performance report described in paragraph (1), the Secretary shall include an explanation of how the Food and Drug Administration is managing the biological product review program to ensure that the user fees collected under subpart 2  [1] are not used to review an application under section 262 (k) of title 42.


[1]  So in original. Probably means subpart 2 of part C.

Source

(June 25, 1938, ch. 675, § 715, as added and amended Pub. L. 112–144, title III, § 308, title IV, § 408,July 9, 2012, 126 Stat. 1025, 1039.)
Amendments

2012—Subsec. (b). Pub. L. 112–144, § 408, added subsec. (b).
Effective Date of 2012 Amendment

Amendment by section 408 ofPub. L. 112–144effective Oct. 1, 2012, see section 405 ofPub. L. 112–144, set out as an Effective and Termination Dates note under section 379j–51 of this title.
Effective Date

Section effective Oct. 1, 2012, see section 305 ofPub. L. 112–144, set out as an Effective and Termination Dates note under section 379j–41 of this title.

The table below lists the classification updates, since Jan. 3, 2012, for this section. Updates to a broader range of sections may be found at the update page for containing chapter, title, etc.

The most recent Classification Table update that we have noticed was Tuesday, August 13, 2013

An empty table indicates that we see no relevant changes listed in the classification tables. If you suspect that our system may be missing something, please double-check with the Office of the Law Revision Counsel.

21 USCDescription of ChangeSession YearPublic LawStatutes at Large
§ 379d-42012112-144 [Sec.] 408126 Stat. 1039
§ 379d-4new2012112-144 [Sec.] 308 "715"126 Stat. 1025

 

LII has no control over and does not endorse any external Internet site that contains links to or references LII.